Skip to Main Content

Author Details

Sudheer Kumar Gara
National Cancer Institute, National Institutes of Health
2005
34
18
PMIDPaper TitleJournal TitlePublished Year
37974213Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.J Exp Clin Cancer Res2023
37974213Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.J Exp Clin Cancer Res2023
32927122UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.J Thorac Oncol2021
34326811Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.Front Endocrinol (Lausanne)2021
32927122UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.J Thorac Oncol2021
34790904Hookah Smoke Mediates Cancer-Associated Epigenomic and Transcriptomic Signatures in Human Respiratory Epithelial Cells.JTO Clin Res Rep2021
34790904Hookah Smoke Mediates Cancer-Associated Epigenomic and Transcriptomic Signatures in Human Respiratory Epithelial Cells.JTO Clin Res Rep2021
34326811Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.Front Endocrinol (Lausanne)2021
31522749Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.Surgery2020
31937621A Combinatorial Strategy for Targeting <i>BRAF</i> <sup>V600E</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).Clin Cancer Res2020
32934779GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3.Oncotarget2020
31522749Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy.Surgery2020
31937621A Combinatorial Strategy for Targeting <i>BRAF</i> <sup>V600E</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).Clin Cancer Res2020
32934779GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3.Oncotarget2020
30327187Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.Surgery2019
31703244<i>NOP53</i> as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer.Genes (Basel)2019
30398411Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.Thyroid2019
30327187Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment.Surgery2019
30620390Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.Cancer2019
31703244<i>NOP53</i> as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer.Genes (Basel)2019
30398411Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.Thyroid2019
30620390Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.Cancer2019
29294023In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.J Clin Endocrinol Metab2018
30301885Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.Nat Commun2018
30250647Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.Oncotarget2018
29294023In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.J Clin Endocrinol Metab2018
29149451Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.Cancer2018
30250647Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response.Oncotarget2018
30301885Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.Nat Commun2018
29149451Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.Cancer2018
28600475Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.Clin Cancer Res2017
28600475Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.Clin Cancer Res2017
29263832To the editor.NPJ Genom Med2017
28114280RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.Oncogene2017
28114280RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.Oncogene2017
29263832To the editor.NPJ Genom Med2017
26324161FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization.World J Surg2016
26324161FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization.World J Surg2016
25488748miR30a inhibits LOX expression and anaplastic thyroid cancer progression.Cancer Res2015
25488748miR30a inhibits LOX expression and anaplastic thyroid cancer progression.Cancer Res2015
25767039Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.Cancer Med2015
26222560Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.N Engl J Med2015
26581001HABP2 Mutation and Nonmedullary Thyroid Cancer.N Engl J Med2015
26446994Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.Nucleic Acids Res2015
26581001HABP2 Mutation and Nonmedullary Thyroid Cancer.N Engl J Med2015
26446994Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.Nucleic Acids Res2015
26222560Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.N Engl J Med2015
25767039Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.Cancer Med2015
24563484A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 Exon 16.J Biol Chem2014
24563484A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 Exon 16.J Biol Chem2014
  • 1 - 50 of 68

Recommended Authors

University of Science and Technology Liaoning
Career Start Year 2009
Number of shared co-authors 0
University of Basel
Career Start Year 2008
Number of shared co-authors 0
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2006
Number of shared co-authors 1
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 0
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Hubei Engineering Research Center for Bio-enzyme Catalysis, Hubei University
Career Start Year 2003
Number of shared co-authors 3
The Ohio State University Comprehensive Cancer Center, Comprehensive Cancer Center
Career Start Year 2002
Number of shared co-authors 2
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 20
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 2
From Foundation Medicine
Career Start Year 1999
Number of shared co-authors 18
Amsterdam University Medical Centers location AMC
Career Start Year 1999
Number of shared co-authors 0
AC Camargo Cancer Center
Career Start Year 1998
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 18
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 1995
Number of shared co-authors 7
RIKEN Center for Integrative Medical Sciences
Career Start Year 1994
Number of shared co-authors 1
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 3
Nova Scotia Health Authority
Career Start Year 1992
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 2
Yantai Affiliated Hospital of Binzhou Medical University
Career Start Year 1991
Number of shared co-authors 2
Uppsala University
Career Start Year 1991
Number of shared co-authors 0
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 0
Yale School of Medicine
Career Start Year 1989
Number of shared co-authors 0
University of Michigan ann arbor
Career Start Year 1989
Number of shared co-authors 6
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Career Start Year 1986
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 2
Broad Institute
Career Start Year 1983
Number of shared co-authors 2

Collaborators

Stanford University School of Medicine
Co-authored papers 22
National Cancer Institute, National Institutes of Health
Co-authored papers 11
Center for Cancer Research
Co-authored papers 10
National Institute of Child Health and Development
Co-authored papers 10
The University of Texas at Austin
Co-authored papers 9
National Cancer Institute (NCI), National Institutes of Health (NIH)
Co-authored papers 6
Frederick National Laboratory for Cancer Research, National Institutes of Health
Co-authored papers 5
Department of Biochemistry and Howard Hughes Medical Institute, Stanford University
Co-authored papers 4
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Georgia Cancer Center, Augusta University
Co-authored papers 3
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Center for Drug Evaluation and Research
Co-authored papers 2
National Institute of Diabetes and Digestive and Kidney Diseases
Co-authored papers 2
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
National Center for Advancing Translational Sciences, National Institutes of Health
Co-authored papers 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 2
Co-authored papers 2
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
National Cancer Institute
Co-authored papers 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Chalmers University of Technology
Co-authored papers 2
Co-authored papers 1
Mayo Clinic Jacksonville
Co-authored papers 1
The University of North Carolina
Co-authored papers 1
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
National Cancer Institute, National Institutes of Health
Co-authored papers 1